Saturday, January 28, 2023
Home Partner News

Partner News

Defence Therapeutics has melanoma vaccine validated

Defence Therapeutics has melanoma vaccine validated

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation...
Defence Therapeutics has US patent accepted for Accum

Defence Therapeutics has US patent accepted for Accum

Defence Therapeutics Inc, a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate...
Defence Therapeutics launch Accum-mRNA vaccine programme

Defence Therapeutics launch Accum-mRNA vaccine programme

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement...

Defence’s novel Accutox intranasal reduces 50% of cancer nodules

Defense Therapeutics, a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies,  has just completed a pre-clinical study using...
Defence Therapeutics are using Accum technology in mRNA vaccines

Defence Therapeutics are using Accum technology in mRNA vaccines

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its...
How dangerous is mould in the home?

How dangerous is mould in the home?

Amid the rise of mould-related health incidents in the UK, Gama Healthcare investigates what can be done to combat the risk of mould in...
Adopt point-of-care diagnostics testing to cut carbon emissions, say over 80% of GPs

Adopt point-of-care diagnostics to cut carbon emissions, say over 80% of GPs

A new study by LumiraDX has found that the majority of the GP workforce believes that point-of-care diagnostics could cut carbon emissions. Point-of-care diagnostics must...
Defence Therapeutics applies Accum technology to cancer vaccines

Defence Therapeutics to begin phase 1 trial for new anti-cancer treatment

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful...
Defence's successful study on the ACCUVAC-PT007 vaccine

Defence’s successful study on the ACCUVAC-PT007 vaccine

Defence Therapeutics Inc. has announced its successful study on its ACCUVAC-PT007 vaccine, which targets cervical cancer. Defence Therapeutics Inc. a Canadian biopharmaceutical company specialised in...
Adopt point-of-care diagnostics testing to cut carbon emissions, say over 80% of GPs

LumiraDx continue rapid microfluidic immunoassay HbA1c test expansion

LumiraDx's rapid microfluidic immunoassay HbA1c test will now be available in Europe, parts of the Middle East, Asia, Latin America, and Africa. Early customers...
Luxembourg government approve Azenta MoU on cold chain solutions

Luxembourg government approve Azenta MoU on cold chain solutions

Azenta, Inc. and the Government of Luxembourg today announced the signing of a Memorandum of Understanding (MoU) to facilitate continued healthcare technology and the...
Defence Therapeutics applies Accum technology to cancer vaccines

Defence Therapeutics applies Accum technology to anti-cancer vaccine

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and...
Defence Therapeutics launches new AccuTOX lung cancer treatment

Defence Therapeutics launches new AccuTOX lung cancer treatment

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start...
Secop Group and B Medical Systems announce cold chain solutions partnership

Secop Group and B Medical Systems announce cold chain solution partnership

A new agreement between Secop Group and B Medical Systems will provide new cold chain solutions for the transportation of vaccines, biospecimens and temperature-sensitive...
Defence's successful study on the ACCUVAC-PT007 vaccine

Defence Therapeutics have been granted patents for their antibody-drug conjugate technology

Defence Therapeutics is pleased to announce that notices of allowance have been issued by the Japanese and Israeli Patent Offices for patent application no....
Diagnostic technology is central to tackling pandemics

Diagnostic technology is central to tackling pandemics

“Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” according to LumiraDx and the...
Defence Therapeutics have been granted patents for their anti drug conjugate technology

Accum A1-reprogrammed vaccine cured 80% of animals with pre-established lymphoma

Defence Therapeutics Inc, a Canadian biopharmaceutical company specialising in developing immune-oncology vaccines and drug delivery technologies, are pleased to report that Defence’s novel vaccine...
Defence Therapeutics applauds United States President on anti-cancer initiative

Defence Therapeutics applauds US President’s anti-cancer initiative

Defence Therapeutics Inc, a Canadian biotech company actively working on accelerating scientific discoveries an products development against cancer, congratulates US President, Joe Biden on...
LumiraDx COVID 19 antigen test is the only test exceeding WHO’s desirable sensitivity target

LumiraDx’s COVID-19 antigen test is the only test exceeding WHO’s desirable sensitivity target

In a Cochrane meta-analysis of 152 studies investigating over 100,000 nose and throat samples and 20 brands of COVID-19 tests, only the LumiraDx assay...
Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells

Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells

Defence Therapeutics has announced groundbreaking news about the development of a novel anti-cancer cellular vaccine using reprogrammed mesenchymal stromal cells. Defence Therapeutics Inc., a Canadian...

Latest Health Partners

Latest Health eBooks

Pin It on Pinterest